Respiratory Depression - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 41 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Respiratory Depression - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Respiratory Depression - Pipeline Review, H1 2015’, provides an overview of the Respiratory Depression’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Respiratory Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Depression and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Respiratory Depression
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Respiratory Depression and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Respiratory Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Respiratory Depression pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Respiratory Depression
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Respiratory Depression pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Respiratory Depression Overview 6
Therapeutics Development 7
Pipeline Products for Respiratory Depression - Overview 7
Pipeline Products for Respiratory Depression - Comparative Analysis 8
Respiratory Depression - Therapeutics under Development by Companies 9
Respiratory Depression - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Respiratory Depression - Products under Development by Companies 12
Respiratory Depression - Companies Involved in Therapeutics Development 13
Cortex Pharmaceuticals, Inc. 13
Galleon Pharmaceuticals 14
Respiratory Depression - Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Target 16
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 23
CX-1739 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
CX-1942 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
CX-2007 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CX-2076 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
doxapram hydrochloride - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
GAL-021 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
GAL-021 Successors - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
tianeptine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Respiratory Depression - Recent Pipeline Updates 32
Respiratory Depression - Dormant Projects 35
Respiratory Depression - Product Development Milestones 36
Featured News & Press Releases 36
Sep 24, 2014: Cortex Pharmaceuticals Announces Phase 1 Funding by the National Institute of Drug Abuse, National Institutes of Health, Under the Small Business Innovation Research Funding Award Program 36
Feb 12, 2014: Revive Therapeutics Announces Encouraging Interim Results from Ongoing Phase 2a Proof-Of-Concept Study of REV-001 for the Prevention of Opioid-Induced Respiratory Depression 36
Sep 20, 2012: Galleon Pharma Reports Positive Results From Second Phase I Study Of GAL-021 For Treatment Of Respiratory Depression 37
May 07, 2012: Galleon Reports Positive Results From Phase I Study Of GAL-021 For Treatment Of Respiratory Depression 38
Aug 24, 2011: Cortex Receives US Patent For Use Of Ampakine Molecules To Treat Respiratory Depression 38
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 40
Disclaimer 41

List of Tables

Number of Products under Development for Respiratory Depression, H1 2015 7
Number of Products under Development for Respiratory Depression - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Respiratory Depression - Pipeline by Cortex Pharmaceuticals, Inc., H1 2015 13
Respiratory Depression - Pipeline by Galleon Pharmaceuticals, H1 2015 14
Assessment by Monotherapy Products, H1 2015 15
Number of Products by Stage and Target, H1 2015 17
Number of Products by Stage and Mechanism of Action, H1 2015 19
Number of Products by Stage and Route of Administration, H1 2015 21
Number of Products by Stage and Molecule Type, H1 2015 22
Respiratory Depression Therapeutics - Recent Pipeline Updates, H1 2015 32
Respiratory Depression - Dormant Projects, H1 2015 35